Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on June 18, 2013. The report discloses the entry into a material agreement regarding the potential sale of common stock. Note: The metadata provided lists "ACHIEVE LIFE SCIENCES, INC.", but the filing text explicitly identifies the registrant as OncoGenex Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses solely on the terms of a new sales agreement.
Material Changes
On June 18, 2013, the Company entered into an At-the-Market Issuance Sales Agreement with MLV & Co. LLC. Key terms include:
- Aggregate Proceeds: Up to $25,000,000.
- Sales Method: "At-the-market" offerings via ordinary brokers' transactions on The NASDAQ Capital Market or other market prices.
- Commission: MLV will receive up to 3.0% of gross sales proceeds.
- Obligation: The Company is not obligated to sell any shares under the agreement.
Guidance, Outlook, and Risks
The filing incorporates the agreement into a previously filed shelf registration statement (Form S-3, File No. 333-184829). The agreement will terminate upon the sale of all subject shares or earlier termination per the agreement's terms. The document includes standard legal disclaimers stating that the disclosure does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume on The NASDAQ Capital Market to assess the potential dilution impact of a $25,000,000 offering.
- Review the full text of the At-the-Market Issuance Sales Agreement (Exhibit 1.1) for specific termination rights and price limitations.
- Confirm the Company's current cash position and capital needs to understand the urgency of utilizing this facility.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.